Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gustavo Rodriguez

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Gynecologic Oncology|February 14, 2017
Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group studyPhuong L Mai, Marion Piedmonte, Paul K Han, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2014
Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199Mark E Sherman, Marion Piedmonte, Phuong L Mai, et al.
Rheumatology Advances in Practice|April 1, 2024
Effectiveness of methotrexate and leflunomide as corticoid-sparing drugs in patients with polymyalgia rheumaticaJuan Pablo Vinicki, Alejandra Cusa, Daniela Domingo, et al.
Stroke (Hoboken, N.J.)|March 12, 2026
Carotid Artery Stenting Outcomes in Comprehensive Stroke Hospitals (CASSH): A Prospective Multicenter StudyMohamad Ezzeldin, Ameer E Hassan, Rime Ezzeldin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2017
Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening TrialsSteven J Skates, Mark H Greene, Saundra S Buys, et al.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|August 19, 2020
Call to Action: SARS-CoV-2 and CerebrovAscular DisordErs (CASCADE)Shahram Abootalebi, Benjamin M Aertker, Mohammad Sobhan Andalibi, et al.
Rheumatology International|December 13, 2018
Reliability of OMERACT ultrasound elementary lesions in gout: results from a multicenter exerciseTomas Cazenave, Victoria Martire, Anthony M Reginato, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 26, 2012
A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriersYuan C Ding, Lesley McGuffog, Sue Healey, et al.
Human Molecular Genetics|May 20, 2011
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriersAntonis C Antoniou, Christiana Kartsonaki, Olga M Sinilnikova, et al.
JAMA|April 8, 2015
Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancerTimothy R Rebbeck, Nandita Mitra, Fei Wan, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Gynecologic Oncology|February 14, 2017
Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group studyPhuong L Mai, Marion Piedmonte, Paul K Han, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2014
Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199Mark E Sherman, Marion Piedmonte, Phuong L Mai, et al.
Rheumatology Advances in Practice|April 1, 2024
Effectiveness of methotrexate and leflunomide as corticoid-sparing drugs in patients with polymyalgia rheumaticaJuan Pablo Vinicki, Alejandra Cusa, Daniela Domingo, et al.
Stroke (Hoboken, N.J.)|March 12, 2026
Carotid Artery Stenting Outcomes in Comprehensive Stroke Hospitals (CASSH): A Prospective Multicenter StudyMohamad Ezzeldin, Ameer E Hassan, Rime Ezzeldin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2017
Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening TrialsSteven J Skates, Mark H Greene, Saundra S Buys, et al.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|August 19, 2020
Call to Action: SARS-CoV-2 and CerebrovAscular DisordErs (CASCADE)Shahram Abootalebi, Benjamin M Aertker, Mohammad Sobhan Andalibi, et al.
Rheumatology International|December 13, 2018
Reliability of OMERACT ultrasound elementary lesions in gout: results from a multicenter exerciseTomas Cazenave, Victoria Martire, Anthony M Reginato, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 26, 2012
A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriersYuan C Ding, Lesley McGuffog, Sue Healey, et al.
Human Molecular Genetics|May 20, 2011
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriersAntonis C Antoniou, Christiana Kartsonaki, Olga M Sinilnikova, et al.
JAMA|April 8, 2015
Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancerTimothy R Rebbeck, Nandita Mitra, Fei Wan, et al.
Pageof 7